Xcellerated T Cells for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study focuses on a new T cell immunotherapy treatment, Xcellerated T CellsTM, for patients with a type of cancer called indolent non-Hodgkin's lymphoma (NHL). The study is designed for patients whose disease has returned or has not responded well to previous treatments, which were no more than four. The main goal of this research is to see if Xcellerated T CellsTM can boost the body's immune response to fight the cancer effectively. This is important because it could potentially offer a new treatment option for patients with this condition. During the study, patients will receive Xcellerated T CellsTM, which are their own T cells that have been activated and multiplied in a lab. The study aims to evaluate the effectiveness and safety of this treatment in these patients. It will also look at changes in the number and type of T- and B-lymphocytes, T cell receptor repertoire, hemoglobin levels, platelet counts, and immunoglobulin levels. In some patients, small samples from malignant lymph nodes and bone marrow will be taken to assess changes in lymphocyte composition and type. Additionally, anti-tumor immune responses will be evaluated in patients who can undergo biopsy of enlarged lymph nodes.